Peer Reviewed
Drug update

Sacubitril–valsartan: changing the paradigm for heart failure with reduced ejection fraction

Christopher Hayward
Abstract

Sacubitril–valsartan represents a new drug class, the angiotensin receptor–neprilysin inhibitors, that shows potential to replace ACE inhibitors in the treatment of selected patients with heart failure with reduced ejection fraction.

Key Points

    Following the recent PARADIGM-HF trial involving sacubitril–valsartan, recommendations on the optimal medical therapy for a significant proportion of patients with heart failure may be on the cusp of change.1,2 The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan has potential to replace ACE inhibitors in the treatment of selected patients with heart failure with reduced ejection fraction.

    Picture credit: © Lightsource/Depositphotos.

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?